Navigation Links
ThromboGenics Announces 2007 Full Year Results
Date:3/13/2008

is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF), which has begun Phase I clinical trials for the treatment of cancer. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospectus.

For further information please contact:

ThromboGenics

Chris Buys
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
2. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
3. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
6. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
7. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
8. EntreMed Announces 2008 Corporate and Clinical Program Priorities
9. Arpida Announces Full Year 2007 Financial Results
10. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
11. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... 2015  Health eCareers, the healthcare industry,s online ... job seekers looking for the flexibility of short-term ... and online tool dedicated exclusively to temporary and ... SHIFT enables employers to quickly find and hire ... diem and other temporary positions, eliminating the time ...
(Date:5/20/2015)... 20, 2015  Marc Tessier-Lavigne, president of The ... $100 million from The Marie-Josée and Henry R. ... building that will be the centerpiece of the ... Henry R. Kravis Research Building, two stories high, ... approximately three city blocks following the shoreline of ...
(Date:5/20/2015)... DIEGO , May 20, 2015  Cypher ... announced a collaboration with Celgene Corporation to apply ... genomic biomarkers that associate with patient response to ... is intended to help accelerate patient access to ... efficiencies in clinical research and development and potentially ...
(Date:5/20/2015)... 2015 Research and Markets ( ... "Bone Morphogenetic Proteins Market (Types : rhBMP-2 ... Oral - Maxillofacial) - Global Industry Analysis, Size, ... report to their offering. The ... on the types of recombinant BMPs, applications, and ...
Breaking Biology Technology:Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2
... 8 Brinks Hofer Gilson & Lione, one ... United States, is pleased to,announce that William F. ... Group, one of the largest nanotechnology practices in ... 10 intellectual property lawyers,influencing the field of Nanotechnology ...
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... solutions, is featuring its,new TB diagnostic test, the ... 2008)., The test, which was introduced to ... needed aid in the diagnosis of Mycobacterium,tuberculosis (TB) ...
... MGT Capital Investments,Inc. (Amex: MGT ), ... Technology ("HCIT") sector, today reported financial results,for the ... an update on,strategic milestones., Tim Paterson-Brown, MGT ... half of 2008 reflect continued progress in the ...
Cached Biology Technology:William F. Prendergast Named One of the Top IP Lawyers in Nanotechnology 2Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008 2MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments 2MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments 3MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments 4MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments 5
(Date:5/11/2015)... 11, 2015  Through a well-rounded UAS delegation representing private ... a strong showing at AUVSI,s Unmanned 2015 conference last week ... Ohio,s UAS industry met with over 200 ... points along the UAS ecosystem. "Our message ... President for Aerospace Rich Knoll . "If you want ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
(Date:5/7/2015)... Sweden , May 7, 2015 ... touch fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest ... and FPC1035 are mainly considered for integration on ... size gives smartphone OEMs increased possibilities to integrate ... The decreased size also improves possibilities for module ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... Drug Administration (FDA) today issued a public health advisory ... to new safety information concerning an unapproved (i.e., "off-label") ... drugs are approved for the treatment of schizophrenia and ... behavioral disorders in elderly patients with dementia have shown ...
... versatile microorganisms ?a bacterium called Pseudomonas putida ?could ... the destruction of the chemical weapon mustard, write ... Biotechnology (http://www.interscience.wiley.com/jctb) this month. , At 40,000 tonnes, ... warfare agents (CWAs). The country faces a race ...
... traveler's diarrhea cases among U.S. travelers to Mexico ... cause of nonbacterial gastroenteritis outbreaks usually associated with ... researchers at the Johns Hopkins Bloomberg School of ... found that the longer travelers stayed at their ...
Cached Biology News:FDA Warns About Antipsychotic Drugs and Elderly 2Could microbes solve Russia's chemical weapons conundrum? 2Norovirus found to cause traveler's diarrhea 2
... 1. 3500 V, 400 mA, 200 W ... linear voltage ramp modes.Linear voltage ramp mode ... strips quickly without danger of overheating.Volt-hour and ... thickness, sample ionic strength, and temperature.Stores and ...
Human Aminopeptidase P1/XPNPEP1 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
Template and primers for preparation of internal control spots...
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
Biology Products: